FDA and CDC Leaders Address the Rare Disease Community

What questions do you have about the recently authorized COVID-19 vaccines? NORD, The ALS Association, Cystic Fibrosis Foundation and Muscular Dystrophy Association are pleased to host a special webinar with leaders from the US Food and Drug Administration (FDA) and the Centers for Disease Control (CDC) to discuss COVID-19 vaccines with the rare disease community.

COVID-19 Vaccines Update: FDA and CDC Leaders Address the Rare Disease Community

The COVID-19 Vaccine and Inherited Metabolic Disease: What You Need to Know

This webinar organized by UK LSD Patient Collaborative Group brought together an expert panel to address questions and concerns relating to the vaccines, addressing misconceptions and myths, and providing practical advice and information for those with an inherited metabolic disease.

National MPS Society’s Advisory on COVID-19 and MPS/ML

Chief Scientific Officer and members of the Scientific Advisory Board of National MPS Society have put together a collection of common questions and answers related to the COVID-19 vaccine rollout, and specific areas of concern for the MPS/ML community. Please click here for more in-depth information

Covid-19 Vaccine’s Impact on Gene Therapy 

What are neutralizing antibodies (NAbs)? How do NAbs impact gene therapy? How do the COVID vaccines impact AAV Nabs? In this webinar organized by Cure Rare Disease , Dr. Federico Mingozzi and Dr. Noah Weisleder speak about Neutralizing Antibodies, the Covid-19 vaccine, and their implications for the future of gene therapy.